This segment focuses on the research, development, manufacturing, and marketing of in vitro diagnostic instruments. Dirui offers a range of analyzers, including biochemical, blood cell, urine, coagulation, chemiluminescence immunoassay, and gynecological secretion analyzers. R&D activities include developing advanced technologies for improved accuracy, speed, and user-friendliness of diagnostic instruments. Technologies employed include automated analysis systems, optical detection methods, and data management software. The therapeutic areas covered include general diagnostics, with applications in hematology, clinical chemistry, and urinalysis. The patient impact is significant, as these instruments aid in the rapid and accurate diagnosis of various diseases, leading to improved patient outcomes. Dirui positions itself as a leading provider of IVD solutions in China, with a focus on innovation and quality. Future opportunities lie in expanding the product portfolio, entering new markets, and integrating AI and data analytics. Regulatory compliance and clinical validation are crucial aspects of this segment, ensuring the safety and efficacy of the instruments. Partnerships with distributors and healthcare providers are essential for market access and customer support.

This segment involves the development, production, and sale of diagnostic reagents and test strips that are used in conjunction with Dirui's IVD instruments. The R&D efforts are focused on creating high-quality reagents and test strips that provide accurate and reliable results. Technologies used include chemical synthesis, immunoassay techniques, and advanced materials science. The therapeutic areas covered include clinical chemistry, hematology, and urinalysis, supporting the diagnosis of a wide range of diseases. The patient impact is direct, as the quality of reagents and test strips directly affects the accuracy of diagnostic results, influencing treatment decisions and patient care. Dirui aims to provide a comprehensive IVD solution by offering both instruments and reagents, enhancing its market position. Future opportunities include expanding the reagent portfolio, developing new test formats, and improving the stability and shelf life of the products. Regulatory compliance and clinical validation are critical to ensure the accuracy and reliability of the reagents. Partnerships with instrument manufacturers and clinical laboratories are essential for market penetration and customer support.